Taibang Biologic Group (Taibang Biologic) formerly, China Biologic Products Holdings Inc, discovers, develops, manufactures and sells human plasma-based biopharmaceutical products in China. Its primary activities include the research and development, production, and sales of blood products and biological products. The company serves the healthcare and biopharmaceutical industries, focusing on blood products such as human albumin, human immunoglobulin, and human coagulation factors.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

China Biologic has undertaken several R&D initiatives to enhance its capabilities in plasma-derived products and medical devices. The company focuses on raising the overall plasma utilization rate through the development of new products, increasing the yield of existing products by optimizing plasma fractionation technologies, and improving the safety of existing products through optimized production processes. Additionally, the company explores new product indications and aims to increase product quality standards using cutting-edge technologies, while also enhancing the convenience of use for doctors and patients by optimizing the production of existing products. The R&D unit of the company is responsible for building and maintaining the company's leading R&D capabilities. This unit has gathered an excellent team of dedicated and highly qualified industry experts. The company has acquired more than 100 patents for plasma-derived products and over 20 patents for sophisticated medical devices.